BR201 (secukinumab biosimilar)
/ BioRay Biopharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 26, 2025
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
(clinicaltrials.gov)
- P1 | N=88 | Completed | Sponsor: BioRay Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Completed
Trial completion • Dermatology • Immunology • Psoriasis
December 03, 2023
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
(clinicaltrials.gov)
- P1 | N=88 | Not yet recruiting | Sponsor: BioRay Pharmaceutical Co., Ltd.
Trial completion date • Trial initiation date • Trial primary completion date • Dermatology • Immunology • Psoriasis
1 to 2
Of
2
Go to page
1